125 related articles for article (PubMed ID: 21051655)
1. MDM2 as a modifier gene in retinoblastoma.
Castéra L; Sabbagh A; Dehainault C; Michaux D; Mansuet-Lupo A; Patillon B; Lamar E; Aerts I; Lumbroso-Le Rouic L; Couturier J; Stoppa-Lyonnet D; Gauthier-Villars M; Houdayer C
J Natl Cancer Inst; 2010 Dec; 102(23):1805-8. PubMed ID: 21051655
[TBL] [Abstract][Full Text] [Related]
2. p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma.
Epistolato MC; Disciglio V; Livide G; Berchialla P; Mencarelli MA; Marozza A; Amenduni M; Hadjistilianou T; De Francesco S; Acquaviva A; Toti P; Cetta F; Ariani F; De Marchi M; Renieri A; Giachino D
J Hum Genet; 2011 Sep; 56(9):685-6. PubMed ID: 21814224
[TBL] [Abstract][Full Text] [Related]
3. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
4. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
5. Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility.
Cao Q; Wang Y; Song X; Yang W
Medicine (Baltimore); 2018 Dec; 97(49):e13547. PubMed ID: 30544467
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
8. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
[TBL] [Abstract][Full Text] [Related]
9. A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1.
Eloy P; Dehainault C; Sefta M; Aerts I; Doz F; Cassoux N; Lumbroso le Rouic L; Stoppa-Lyonnet D; Radvanyi F; Millot GA; Gauthier-Villars M; Houdayer C
PLoS Genet; 2016 Feb; 12(2):e1005888. PubMed ID: 26925970
[TBL] [Abstract][Full Text] [Related]
10. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
11. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma.
de Oliveira Reis AH; de Carvalho IN; de Sousa Damasceno PB; Ferman SE; Lucena E; Lopez-Camelo JS; Seuánez HN; Vargas FR
Pediatr Blood Cancer; 2012 Jul; 59(1):39-43. PubMed ID: 22180099
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype correlations in hereditary familial retinoblastoma.
Taylor M; Dehainault C; Desjardins L; Doz F; Levy C; Sastre X; Couturier J; Stoppa-Lyonnet D; Houdayer C; Gauthier-Villars M
Hum Mutat; 2007 Mar; 28(3):284-93. PubMed ID: 17096365
[TBL] [Abstract][Full Text] [Related]
13. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
14. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
Bougeard G; Baert-Desurmont S; Tournier I; Vasseur S; Martin C; Brugieres L; Chompret A; Bressac-de Paillerets B; Stoppa-Lyonnet D; Bonaiti-Pellie C; Frebourg T
J Med Genet; 2006 Jun; 43(6):531-3. PubMed ID: 16258005
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
16. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
17. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
18. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
19. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
[TBL] [Abstract][Full Text] [Related]
20. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
